"Antibodies, Monoclonal" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Antibodies produced by a single clone of cells.
Descriptor ID |
D000911
|
MeSH Number(s) |
D12.776.124.486.485.114.224 D12.776.124.790.651.114.224 D12.776.377.715.548.114.224
|
Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Antibodies, Monoclonal".
Below are MeSH descriptors whose meaning is more specific than "Antibodies, Monoclonal".
This graph shows the total number of publications written about "Antibodies, Monoclonal" by people in this website by year, and whether "Antibodies, Monoclonal" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1995 | 3 | 6 | 9 |
1996 | 1 | 7 | 8 |
1997 | 7 | 10 | 17 |
1998 | 4 | 6 | 10 |
1999 | 4 | 5 | 9 |
2000 | 6 | 7 | 13 |
2001 | 4 | 11 | 15 |
2002 | 7 | 17 | 24 |
2003 | 6 | 15 | 21 |
2004 | 6 | 8 | 14 |
2005 | 14 | 12 | 26 |
2006 | 13 | 7 | 20 |
2007 | 13 | 12 | 25 |
2008 | 18 | 16 | 34 |
2009 | 20 | 8 | 28 |
2010 | 17 | 7 | 24 |
2011 | 18 | 13 | 31 |
2012 | 6 | 11 | 17 |
2013 | 11 | 9 | 20 |
2014 | 16 | 8 | 24 |
2015 | 14 | 13 | 27 |
2016 | 18 | 13 | 31 |
2017 | 23 | 14 | 37 |
2018 | 33 | 7 | 40 |
2019 | 17 | 10 | 27 |
2020 | 15 | 21 | 36 |
2021 | 19 | 17 | 36 |
2022 | 3 | 17 | 20 |
2023 | 5 | 15 | 20 |
2024 | 11 | 8 | 19 |
To return to the timeline,
click here.
Below are the most recent publications written about "Antibodies, Monoclonal" by people in Profiles.
-
Complement factor H targeting antibody GT103 in refractory non-small cell lung cancer: a phase 1b dose escalation trial. Nat Commun. 2025 Jan 02; 16(1):93.
-
Virus Protein-Specific Immune Responses in Selective Depletion of Lymphocyte Populations Using Monoclonal Antibodies in Bolivian Squirrel Monkeys (Saimiri boliviensis boliviensisv). Viral Immunol. 2025 Jan-Feb; 38(1):12-22.
-
Association of the time of day of chemoradiotherapy and durvalumab with tumor control in lung cancer. Radiother Oncol. 2025 Feb; 203:110658.
-
Structural characterization of human monoclonal antibodies targeting uncommon antigenic sites on spike glycoprotein of SARS-CoV. J Clin Invest. 2024 Nov 26; 135(3).
-
Protective threshold of a potent neutralizing Zika virus monoclonal antibody in rhesus macaques. J Virol. 2024 Dec 17; 98(12):e0142924.
-
Emapalumab Treatment in Patients With Rheumatologic Disease-Associated Hemophagocytic Lymphohistiocytosis in the United States: A Retrospective Medical Chart Review Study. Arthritis Rheumatol. 2025 Feb; 77(2):226-238.
-
Intravenous Golimumab in Children With Polyarticular-Course Juvenile Idiopathic Arthritis: Long-Term Extension of an Open-Label Phase III Study. J Rheumatol. 2024 Nov 01; 51(11):1125-1134.
-
A Phase Ib/II Randomized Clinical Trial of Oleclumab with or without Durvalumab plus Chemotherapy in Patients with Metastatic Pancreatic Ductal Adenocarcinoma. Clin Cancer Res. 2024 Oct 15; 30(20):4609-4617.
-
CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors. Nature. 2024 Nov; 635(8038):462-471.
-
Recurrent SARS-CoV-2 spike mutations confer growth advantages to select JN.1 sublineages. Emerg Microbes Infect. 2024 Dec; 13(1):2402880.